全文获取类型
收费全文 | 257篇 |
免费 | 21篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 12篇 |
妇产科学 | 1篇 |
基础医学 | 24篇 |
口腔科学 | 2篇 |
临床医学 | 56篇 |
内科学 | 47篇 |
神经病学 | 37篇 |
特种医学 | 16篇 |
外科学 | 22篇 |
预防医学 | 9篇 |
药学 | 18篇 |
中国医学 | 1篇 |
肿瘤学 | 34篇 |
出版年
2023年 | 4篇 |
2022年 | 2篇 |
2021年 | 7篇 |
2020年 | 1篇 |
2019年 | 12篇 |
2018年 | 10篇 |
2017年 | 5篇 |
2016年 | 9篇 |
2015年 | 13篇 |
2014年 | 10篇 |
2013年 | 17篇 |
2012年 | 21篇 |
2011年 | 20篇 |
2010年 | 11篇 |
2009年 | 13篇 |
2008年 | 9篇 |
2007年 | 13篇 |
2006年 | 11篇 |
2005年 | 12篇 |
2004年 | 16篇 |
2003年 | 5篇 |
2002年 | 4篇 |
2001年 | 1篇 |
2000年 | 8篇 |
1999年 | 3篇 |
1998年 | 4篇 |
1997年 | 4篇 |
1996年 | 2篇 |
1995年 | 1篇 |
1994年 | 2篇 |
1993年 | 1篇 |
1992年 | 2篇 |
1991年 | 3篇 |
1990年 | 9篇 |
1989年 | 3篇 |
1988年 | 2篇 |
1987年 | 3篇 |
1986年 | 2篇 |
1985年 | 1篇 |
1981年 | 1篇 |
1978年 | 1篇 |
1977年 | 1篇 |
1968年 | 1篇 |
排序方式: 共有280条查询结果,搜索用时 15 毫秒
31.
32.
33.
L. E. Van den Hove P. Meeus A. Derom H. Demuynck G. E. G. Verhoef P. Vandenberghe M. A. Boogaerts 《Annals of hematology》1998,76(6):249-256
The distribution of 27 T-, B-, and natural killer-cell subsets in the peripheral blood of 40 patients with multiple myeloma
(MM), ten patients with monoclonal gammopathy of undetermined significance (MGUS), and 40 healthy donors was investigated
by means of classical univariate statistics and advanced multivariate data-analytical techniques. The latter approach was
used to describe, represent, and analyze lymphocyte subset distribution in a two-dimensional correlation biplot, allowing
comparison of complex lymphocyte profiles (i.e., compound lymphocyte subset distributions) of individual subjects rather than
isolated subset values of selected patient and/or donor groups. The correlation biplot revealed that, in accordance with the
univariate statistics, the MM patients were characterized by marked shifts towards CD8+, CD57+, CD62L–, CD(16+56)+, and HLA-DR+ T cells, suggesting in vivo immune activation. The activation profile was most markedly observed in treated MM patients in
the advanced disease stage category. The lymphocyte profiles of MGUS patients were heterogeneous, with approximately half
of them located in the swarm of MM patients and the other half in the swarm of healthy donors. Although the univariate statistics
revealed significant differences between MGUS patients and healthy donors only within the B-cell compartment, the correlation
biplot revealed that two MGUS patients clearly had a typical T-cell activation profile similar to that of the MM patients.
One MGUS patient with a T-cell activation profile progressed 13 months later to a stage IA MM and required chemotherapy. A
marked lymphocyte profile shift in one MM patient was associated with terminal and aggressive disease transformation. Our
study illustrates further the practical use of correlation biplots for the detection of aberrant lymphocyte profiles and/or
profile shifts in individual patients.
Received: 15 May 1997 / Accepted: 24 April 1998 相似文献
34.
Rafii S Dias S Meeus S Hattori K Ramachandran R Feuerback F Worgall S Hackett NR Crystal RG 《Circulation research》2001,88(9):903-910
Intravascular introduction of replication-deficient adenoviral vectors (Advectors) provides an ideal model of delivery of transgenes for the treatment of various vascular abnormalities. On the basis of the knowledge that Advectors can induce inflammatory responses after intravascular administration, we speculated that cellular activation by Advector infection could directly modulate the endothelial cell (EC) adhesion molecule/chemokine expression repertoire. Infection of human umbilical vein ECs or bone marrow microvascular ECs with an E1(-)E4(+) Advector resulted in the upregulation of intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and CD34, but not E-selectin, P-selectin, CD36, CD13, CD44, HLA-DR or PECAM. Upregulation of ICAM-1, VCAM-1, and CD34 was apparent 12 hours after infection and persisted for weeks after infection. Selective induction of adhesion molecules was mediated by the presence of the E4 gene in the Advector, because infection of ECs with an E1(-)E4(-) Advector had no effect on adhesion molecule expression. ECs infected with E1(-)E4(+) Advector, but not those infected with E1(-)E4(-) Advector, supported the adhesion of leukocytes. Monoclonal antibodies to ICAM-1 and VCAM-1 inhibited adhesion of leukocytes to E1(-)E4(+)-infected ECS: Infection of the ECs with E1(-)E4(+) Advector, but not E1(-)E4(-) Advector, resulted in downregulation of expression of chemocytokines, including interleukin-8, MCP-1, RANTES, and GM-CSF. Nonetheless, a large number of leukocytes migrated through ECs infected with E1(-)E4(+), but not those infected with E1(-)E4(l-), in response to exogenous chemokines. These results demonstrate that infection of ECs with E1(-)E4(+) Advectors, but not E1(-)E4(-) Advectors, may directly augment inflammatory responses by upregulating expression of adhesion molecules and enhancing migration through Advector-infected ECs and suggest that E1(-)E4(-) Advectors may be a better choice for gene-transfer strategies directed to the ECS: 相似文献
35.
Stella M Mithieux F Meeus P Kaemmerlen P Lafon C Rivoire M 《Journal of surgical oncology》2006,93(4):268-272
BACKGROUND AND OBJECTIVES: Cryosurgical ablation (CSA) allows the focal destruction of unresectable liver metastases after previous liver resection. The abdominal approach may be difficult for recurrent colorectal cancer metastases located in the upper part of the remaining liver, close to the inferior vena cava (IVC), the hepatic veins, and the diaphragm. A transpleurodiaphragmatic access was assessed for safety and efficacy. METHODS: Between September 1999 and July 2004, 13 patients with recurrent unresectable colorectal liver metastases underwent transpleurodiaphragmatic CSA via limited right thoracotomy. Seventeen lesions were treated; median diameter was 31 mm (range 13-40 mm). One to three cryoprobes were used, depending on the size and location of metastases. RESULTS: There was no operative death; three patients developed minor complications (23%). Median hospital stay was 10 days (8-14 days). After a median follow-up of 26 months (range 8-69 months), 9 patients were alive, and 5 were disease-free. Six patients had liver recurrences outside the cryolesion. Median disease free survival was 12 months with 60% 3-year survival after CSA and 58% 5-year survival after first liver surgery. CONCLUSIONS: Transpleurodiaphragmatic CSA is safe and effective in selected patients with unresectable recurrent liver metastases from colorectal cancer. 相似文献
36.
Blay JY Bonvalot S Fayette J Stockle E Ray-Coquard I Coindre JM Duffaud F Taieb S Sunyach MP Ranchere D Meeus P Le Cesne A Bui BN 《Bulletin du cancer》2006,93(11):1093-1098
This document describe s the proposed clinical practices guidelines for neoadjuvant chemotherapy in soft tissue sarcomas proposed by the French Sarcoma Group.Neo-adjuvant chemotherapy remains an experimental therapeutic procedure in soft tissue sarcomas. Neo-adjuvant chemotherapy may be proposed in three different types of situations: 1) a locally advanced tumor, non accessible to R0 or 1 removal of the lesion. Its objective is there to allow for R0 or R1 surgical removal of the tumor. 2) A locally advanced tumor, accessible to R0 or 1 removal of the lesion, but with a mutilating surgery (amputation). Its objective is there to allow for R0 or R1 conservative surgical removal of the tumor. In both situation, the strategy should be discussed beforehand in a multidisciplinary specialized consultation for sarcoma. 3) In the case where complete (R0 or R1) surgical removal of the tumor can be performed, neooadjuvant chemotherapy has no demonstrated role. The only randomized phase III clinical trial testing neo-adjuvant chemotherapy in this setting, i.e. the STBSG 62871 STBSG trial, failed to demonstrate any benefit in terms of overall or progression free survival. The selection of the type of chemotherapy regimen given in the neoadjuvant setting should be discussed in a multidisciplinary setting, considering the age and the general status of the patient; young patients, without associated concomittent illnesses should be proposed for a combined chemotherapy regimen, combining doxorubicin (> or = 50 mg/m2) and ifosfamide (> 5 g/m2) on the basis of randomized trials demonstrating an improvement of response rate versus single agent therapy with doxorubine. In elderly and/or frail patients, conversely, single agent doxorubicin may be the preferred option. 相似文献
37.
J Chauvergne P Cappelaere P Fargeot L Meeus J Gary-Bobo T Klein B Clavel M David 《Bulletin du cancer》1988,75(1):9-22
Two hundred and nine patients, with locoregional or metastatic recurrences of head and neck epidermoid carcinoma, were randomized to receive a palliative chemotherapy. The chemotherapy regimens were delivered every 3 weeks, and consisted in (1) cisplatin, 80 mg/m2 given alone (CDDP regimen), or (2) in combination with vincristine, 1 mg, methotrexate 10 mg/m2 d 1, 2, 3, and bleomycin 10 mg/m2, d 1, 2 and 3 (1040 regimen). Short-term results were better for patients treated by the 1040 regimen, with a 30% response rate (including 4 complete responses) vs 15% with the CDDP regimen (P = 0.01). A superiority of combination chemotherapy was found for all tumoral sites, but was particularly significant for pulmonary and cutaneous metastases, in previously un irradiated areas (P = 0.001). Tolerance was significantly better with the CDDP regimen (P = 0.001); severe side effects, affecting mainly general status, digestive tract and bone marrow were encountered in 5% of the patients in the CDDP group, vs 21% in the 1040 group, with one death related to pancytopenia. The median duration of remissions was not statistically different in the 2 groups, as well as the 2 years overall survival. Among responders, the survival was slightly better in those treated with CDDP alone; moreover, the quality of long term results was found highly correlated with a good initial general status, and with low levels of side effects. Those results confirm recent data of the literature, and lead to the following conclusions: (1) combination chemotherapy with CDDP give a better response rate than CDDP alone, (2) response rate doesn't influence overall duration of survival, (3) tolerance to treatment is crucial to preserve quality of life, and thus, (4) palliative chemotherapy in head and neck cancer should be efficient but also as short of intensity as possible. 相似文献
38.
Bettina Wagner Heather Freer Alicia Rollins David Garcia-Tapia Hollis N. Erb Christopher Earnhart Richard Marconi Patrick Meeus 《Clinical and Vaccine Immunology : CVI》2012,19(4):527-535
Lyme disease in the United States is caused by Borrelia burgdorferi
sensu stricto, which is transmitted to mammals by infected ticks. Borrelia spirochetes differentially express immunogenic outer surface proteins (Osp). Our aim was to evaluate antibody responses to Osp antigens to aid the diagnosis of early infection and the management of Lyme disease. We analyzed antibody responses during the first 3 months after the experimental infection of dogs using a novel multiplex assay. Results were compared to those obtained with two commercial assays detecting C6 antigen. Multiplex analysis identified antibodies to OspC and C6 as early as 3 weeks postinfection (p.i.) and those to OspF by 5 weeks p.i. Antibodies to C6 and OspF increased throughout the study, while antibodies to OspC peaked between 7 and 11 weeks p.i. and declined thereafter. A short-term antibody response to OspA was observed in 3/8 experimentally infected dogs on day 21 p.i. Quant C6 enzyme-linked immunosorbent assay (ELISA) results matched multiplex results during the first 7 weeks p.i.; however, antibody levels subsequently declined by up to 29%. Immune responses then were analyzed in sera from 125 client-owned dogs and revealed high agreement between antibodies to OspF and C6 as robust markers for infection. Results from canine patient sera supported that OspC is an early infection marker and antibodies to OspC decline over time. The onset and decline of antibody responses to B. burgdorferi Osp antigens and C6 reflect their differential expression during infection. They provide valuable tools to determine the stage of infection, treatment outcomes, and vaccination status in dogs. 相似文献
39.
40.